| Breakdown | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 753.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.94K | 0.00 | 0.00 | -1.27K | -17.95K |
| EBITDA | -1.67M | -1.77M | 230.30K | -2.68M | -2.57M |
| Net Income | -1.64M | -1.77M | 342.50K | -2.66M | -2.59M |
Balance Sheet | |||||
| Total Assets | 4.33M | 5.91M | 7.52M | 818.64K | 2.92M |
| Cash, Cash Equivalents and Short-Term Investments | 4.31M | 5.52M | 7.20M | 485.78K | 2.35M |
| Total Debt | 288.96K | 183.50K | 183.50K | 183.50K | 13.50K |
| Total Liabilities | 789.61K | 790.12K | 639.70K | 829.37K | 423.13K |
| Stockholders Equity | 3.54M | 5.14M | 6.91M | 15.68K | 2.53M |
Cash Flow | |||||
| Free Cash Flow | -931.94K | -962.32K | -847.92K | -755.12K | -1.99M |
| Operating Cash Flow | -931.94K | -962.32K | -847.92K | -755.12K | -1.99M |
| Investing Cash Flow | 662.09K | 973.99K | -5.34M | -338.61K | -622.47K |
| Financing Cash Flow | 117.00K | 0.00 | 6.24M | 194.00K | 3.54M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
67 Neutral | C$10.31M | 0.09 | 75.06% | ― | 486.23% | 478.94% | |
66 Neutral | C$6.51M | 11.28 | 42.23% | 7.52% | -54.61% | 273.14% | |
49 Neutral | C$8.49M | -0.44 | -70.07% | ― | 53.55% | -289.42% | |
49 Neutral | C$13.86M | 2.68 | -23.79% | ― | ― | 66.12% | |
45 Neutral | C$33.45M | -0.96 | -32.32% | ― | -54.44% | -78.24% | |
44 Neutral | C$12.96M | 1.75 | -113.97% | ― | -19.49% | -25.00% |
FutureGen Industries reported significant realized gains from several portfolio investments, underscoring the effectiveness of its active management strategy in the healthcare and biotech space. By recycling capital from successful exits, the firm reinforces its ability to fund new opportunities and potentially enhance returns for shareholders, while deepening its exposure to innovative medical technologies.
From a modest $31,175 position in Canadian cancer-therapy developer Onco-Innovations, FutureGen realized gains of about $765,000 after selling 500,000 shares in 2025, highlighting strong value creation in precision oncology. The company also monetized part of its stake in sepsis-focused ASEP Medical Holdings, turning an original Safecoat Medical investment into over $118,000 in gains as ASEP advances rapid diagnostics and peptide-based therapies targeting antibiotic-resistant infections.
FutureGen further booked gains of roughly $167,000 from its indirect investment in psychedelic-drug developer Core One Labs, after its private 1254571 B.C. Ltd. holding converted into COOL shares and milestone-related bonus stock. The exit demonstrates the firm’s willingness to back high-risk, high-potential platforms in psychedelic medicine and then crystallize profits as assets mature, bolstering cash generation while maintaining strategic exposure to frontier biotech fields.
The most recent analyst rating on (TSE:LITT) stock is a Hold with a C$0.29 price target. To see the full list of analyst forecasts on Roadman Investments stock, see the TSE:LITT Stock Forecast page.
FutureGen Industries Corp. has retained Venture Liquidity Providers Inc. to provide market-making services for its common shares, aiming to support an orderly trading market on the TSX Venture Exchange. The three-month agreement, carried out through registered broker W.D. Latimer Co. Ltd. and renewable monthly, underscores the company’s efforts to improve share liquidity and trading stability without diluting existing shareholders, as VLP is compensated solely in cash and holds no interest in the company or its securities.
The most recent analyst rating on (TSE:LITT) stock is a Hold with a C$0.34 price target. To see the full list of analyst forecasts on Roadman Investments stock, see the TSE:LITT Stock Forecast page.
FutureGen Industries Corp. has stated that its management is unaware of any material change in the company’s operations that would explain a recent surge in trading activity, following a request for clarification from the Canadian Investment Regulatory Organization. The disclosure suggests that the heightened market interest is not driven by undisclosed operational developments, aiming to reassure investors and uphold transparency in the company’s market communications.
The most recent analyst rating on (TSE:LITT) stock is a Hold with a C$0.19 price target. To see the full list of analyst forecasts on Roadman Investments stock, see the TSE:LITT Stock Forecast page.
FutureGen Industries Corp. plans to raise up to $500,000 through a non-brokered private placement of 3,571,428 units priced at $0.14, each consisting of one common share and one warrant exercisable at $0.18 for 36 months. The financing, which may include finders’ fees and warrants and is subject to regulatory approval and standard resale restrictions, will fund general corporate and working capital needs, including operational initiatives, research and development objectives, and investor relations, signaling the firm’s ongoing effort to bolster its balance sheet and support its growth-focused investment strategy.
The most recent analyst rating on (TSE:LITT) stock is a Hold with a C$0.19 price target. To see the full list of analyst forecasts on Roadman Investments stock, see the TSE:LITT Stock Forecast page.
FutureGen Industries Corp. has outlined an expanded investment strategy that pivots its portfolio toward high-growth, innovation-led technology sectors, including defense systems, artificial intelligence, biotechnology, robotics and quantum computing. Under the leadership of CEO Dr. Kristian Thorlund, the firm is repositioning itself to operate in an ETF-style model, offering investors diversified access to both early-stage innovators and established technology companies across these markets, which are collectively forecast to experience substantial global expansion over the next decade. By aligning its mandate with sectors expected to see robust long-term growth, FutureGen aims to enhance its industry positioning as a diversified technology-focused investment platform and to capture value creation opportunities for shareholders across multiple emerging technology verticals.
The most recent analyst rating on (TSE:LITT) stock is a Hold with a C$0.19 price target. To see the full list of analyst forecasts on Roadman Investments stock, see the TSE:LITT Stock Forecast page.
The company announced it will change its name to FutureGen Industries Corp. effective December 22, 2025, while keeping its existing trading symbol (LITT). This rebranding reflects a strategic shift aimed at reinforcing its position in the industry, signaling a renewed focus and commitment to innovation under the new brand identity.